Department of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA; email:
Annu Rev Med. 2020 Jan 27;71:137-148. doi: 10.1146/annurev-med-052918-122440.
The microbiome is an integrated part of the human body that can modulate a variety of disease processes and affect prognosis, treatment response, complications, and outcomes. The importance of allogeneic hematopoietic cell transplantation in cancer treatment has resulted in extensive investigations on the interaction between the microbiome and this treatment modality. These investigations are beginning to lead to clinical trials of microbiome-targeted interventions. Here we review some of these discoveries and describe strategies being investigated to manipulate the microbiome for favorable outcomes, such as the proper selection and timing of antibiotics, type of diet and route of administration, probiotics, prebiotics, and fecal microbiota transplantation.
微生物组是人体的一个整合部分，可以调节多种疾病过程，并影响预后、治疗反应、并发症和结局。异基因造血细胞移植在癌症治疗中的重要性导致了对微生物组与这种治疗方式之间相互作用的广泛研究。这些研究开始导致针对微生物组靶向干预的临床试验。在这里，我们回顾了其中的一些发现，并描述了正在研究的策略，以操纵微生物组以获得有利的结果，例如适当选择和时机使用抗生素、饮食类型和给药途径、益生菌、益生元和粪便微生物组移植。
